Table 1. Demographic data and receptor gene expression of patients and healthy controls.
| Patients (n = 124) | Controls (n = 57) | t/χ2 | p | |
|---|---|---|---|---|
| Age (years) | 36.65 ± 9.74 | 36.19 ± 10.60 | −0.43 | 0.67 |
| Male | 84 (67.74%) | 36 (63.16%) | 0.37 | 0.55 |
| Education (years) | 9.74 ± 1.75 | 10.19 ± 1.96 | −1.26 | 0.22 |
| Age of initial use (years) | 31.87 ± 10.77 | |||
| Duration of use (months) | 22.21 ± 31.73 | |||
| Average dose one time (g) | 0.44 ± 0.39 | |||
| GRIA2 (pg/ml) | 32.58 ± 10.46 | 23.56 ± 9.68 | 5.18 | 0.00 |
| GABRA1 (ng/ml) | 1.09 ± 0.79 | 1.57 ± 0.93 | −2.49 | 0.02 |
Patients: methamphetamine-use disorder patients; GRIA2: glutamate receptor, ionotropic, AMPA 2; GABRA1: gamma-aminobutyric acid type A receptor alpha1 subunit.